Bid opportunityClosed
Human Hindbrain Organoid Functional Assay Services.
HEALTH AND HUMAN SERVICES, DEPARTMENT OF › FOOD AND DRUG ADMINISTRATION › FDA OFFICE OF ACQ GRANT SVCS
Response deadlineSep 17, 2026 10:30 AM EDT
View official notice on SAM.gov ↗ (opens in a new tab)
Verify before acting. Users must verify deadlines, amendments, attachments, eligibility, and submission requirements on the official SAM.gov notice.
Read the Data Disclaimer.
Key decision factors
- Response deadline
- Sep 17, 2026 10:30 AM EDT
- Posted
- Sep 11, 2026 12:00 AM EDT
- Notice type
- Combined Synopsis/Solicitation
- Set-aside
- No Set aside used
- PSC
- B504 — Chemical/Biological Studies and Analysis
- Place of performance
- Not specified
- Current status
- Closed
Notice details
- Official status
- Closed
- Normalized group
- Bid opportunity
- Notice ID
- 0a2d3e56451c4afa948835a62000bb09
- Solicitation number
- RFQ_CDR-2026-135968
Description
Displayed as sanitized plain text from SAM.gov. Retrieved Sep 12, 2026 10:23 PM EDT.
The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Division of Applied Regulatory Science (DARS), intends to award a sole-source, Firm-Fixed-Price purchase order to OrganoTherapeutics SARL for Human iPSC-Derived Hindbrain Organoid Functional Assay Services. The requirement includes the provision of human induced pluripotent stem cell (iPSC)-derived hindbrain organoids and associated materials necessary to support in vitro research evaluating drug-induced effects on respiratory-relevant neural circuits. The contractor will also perform functional characterization of the organoids using three-dimensional multi-electrode array (3D MEA) technology to assess electrophysiological responses to drugs known to affect respiratory function. The functional characterization includes testing FDA-identified drug and reversal-agent combinations, MEA measurements, evaluation of batch-to-batch reproducibility, collection of exposed drug solutions for FDA verification, data analysis, and delivery of raw data, analyzed data, analysis files, and study reports. The requirement also includes twelve scheduled deliveries of human hindbrain organoids to the FDA White Oak Campus. The first delivery will consist of 96 organoids, with subsequent deliveries consisting of 48 organoids each. Functional characterization will be performed at the contractor's laboratory. The anticipated period of performance is eighteen (18) months from the date of award. This acquisition is being conducted as a commercial service acquisition under RFO FAR Part 12. The Government's decision to restrict competition is documented pursuant to RFO FAR 12.102(a). Market research identified OrganoTherapeutics SARL as the only source capable of satisfying the Government's complete requirement for both the required human hindbrain organoids and associated functional assay services. This notice is not intended to restrict consideration of any responsible source capable of meeting the Government's complete requirement. All responsible sources may submit a quotation and supporting capability information by the response date identified in this notice. Any timely response demonstrating the capability to satisfy the Government's complete requirement will be considered by the Contracting Officer prior to award. NAICS: 541714 PSC: B504 – Special Studies/Analysis – Chemical/Biological Place of Delivery: FDA White Oak Campus, Silver Spring, Maryland Place of Service Performance: Contractor's laboratory
Personalized relevance
Would this fit your company?
Create company profile information with a free account to see a deterministic, explainable relevance score. Matching does not determine eligibility or win probability.
Create Free Account
Pursuit risk (separate from your match score)
Strong pursuit warning
This notice contains language indicating a sole-source or otherwise restricted procurement. Review the cited evidence before investing time in a response.
Detected in
- Description“The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Division of Applied Regulatory Science (DARS), intends to award a sole-source, Firm-Fixed-Price purchase order to OrganoTherape”
- Description“ion under RFO FAR Part 12. The Government's decision to restrict competition is documented pursuant to RFO FAR 12.102(a). Market research identified OrganoTherapeutics SARL as the only source capable of satisfying the Go”
Pursuit risk is evaluated separately from your match score above and never changes it. This is not a legal or eligibility determination — verify against the official SAM.gov notice and attachments.